CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 58.69 CNY 0.19% Market Closed
Market Cap: 9.5B CNY

Wall Street
Price Targets

Price Targets Summary
CanSino Biologics Inc

Wall Street analysts forecast CanSino Biologics Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CanSino Biologics Inc is 76.7 CNY with a low forecast of 72.44 CNY and a high forecast of 82.61 CNY.

Lowest
Price Target
72.44 CNY
23% Upside
Average
Price Target
76.7 CNY
31% Upside
Highest
Price Target
82.61 CNY
41% Upside
CanSino Biologics Inc Competitors:
Price Targets
3933
United Laboratories International Holdings Ltd
10% Upside
053030
Binex Co Ltd
87% Upside
GRANULES
Granules India Ltd
27% Upside
HITI
High Tide Inc
126% Upside
605507
Guobang Pharma Ltd
42% Upside
ANCR
Animalcare Group PLC
18% Upside

Revenue
Forecast

Revenue Estimate
CanSino Biologics Inc

The compound annual growth rate of CanSino Biologics Inc's revenue for the next 3 years is 30%.

N/A
Past Growth
30%
Estimated Growth
Estimates Accuracy
-26%
Average Miss

Operating Income
Forecast

Operating Income Estimate
CanSino Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
CanSino Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CanSino Biologics Inc's stock price target?
Price Target
76.7 CNY

According to Wall Street analysts, the average 1-year price target for CanSino Biologics Inc is 76.7 CNY with a low forecast of 72.44 CNY and a high forecast of 82.61 CNY.

What is CanSino Biologics Inc's Revenue forecast?
Projected CAGR
30%

The compound annual growth rate of CanSino Biologics Inc's revenue for the next 3 years is 30%.

Back to Top